59663-96-6

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 4-(hydroxyMethyl)picolinate is used as a chelating agent for metal ions, which is crucial in the development of pharmaceutical compounds that require metal ion binding for their therapeutic effects. Its ability to chelate metals can also contribute to its potential use in treating metal-related disorders or in the formulation of drugs that need to be protected from metal-catalyzed degradation.
Used in Antimicrobial Applications:
Due to its potential antimicrobial properties, ethyl 4-(hydroxyMethyl)picolinate can be utilized as an antimicrobial agent in various settings, such as in the development of new antibiotics or as a preservative in pharmaceutical formulations to prevent microbial contamination.
Used in Antioxidant Formulations:
Ethyl 4-(hydroxyMethyl)picolinate may be used as an antioxidant in the pharmaceutical and nutraceutical industries to protect against oxidative stress and support overall health. Its antioxidant properties could be harnessed in formulations designed to combat free radicals and prevent oxidative damage in biological systems.
Used in Chemical Synthesis:
In the chemical industry, ethyl 4-(hydroxyMethyl)picolinate can be used as a building block or intermediate in the synthesis of more complex organic compounds, including other pharmaceuticals, agrochemicals, or specialty chemicals that require its unique structural features.
Used in Research and Development:
Ethyl 4-(hydroxyMethyl)picolinate serves as a valuable compound in research settings, where it can be studied for its biological activities, mechanisms of action, and potential applications in drug discovery and development. Its unique structure and properties make it an interesting subject for scientific investigation and innovation.

Upstream product

• 141-52-6 sodium ethanolate 
• 117423-43-5 2-cyano-4-[{(tert-butyldimethylsilyl)oxy}methyl]pyridine 
• 586-95-8 pyridine-4-methanol 
• 64-17-5 ethanol 
• 71935-32-5 2-Cyano-4-(hydroxymethyl)pyridine 
• 117423-42-4 4-<<(tert-butyldimethylsilyl)oxy>methyl>pyridine N-oxide 
• 117423-41-3 4-((tert-butyldimethylsilyloxy)methyl)pyridine 

Relevant academic research and scientific papers

NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

A subject of the present invention is to provide a novel aromatic five- or six-memberd heterocyclic derivative having 4-pyridylalkylthio as a substituent or a salt thereof which is useful as a pharmaceutical. Compound represented by the following general formula [I] or salts thereof are useful as therapeutic agents for diseases in which angiogenesis or augmentation of vascular permeability is involved. In the formula, ring "A" is a benzene ring or an aromatic five- or six-memberd heterocycle which can be fused with a cycloalkane ring, "B" is alkylene, R1 and R2, the same or different, are H, OH, substituted or unsubstituted alkoxy and the like, X and Y, the same or different, are group(s) selected from H, halogen, OH, substituted or unsubstituted alkoxy and the like respectively, p is 0, 1 or 2, and q is 0 or 1.

Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade

The present invention is concerned with the phosphonic acids of formula I STR1 wherein one or both of the acidic hydroxy groups of the phosphonic acid moiety may be functionalized in form of pharmaceutically acceptable mono- or di- esters; wherein Y represents optionally substituted 2-carboxypyrrolidinyl, 2-carboxy-2,5-dihydropyrrolyl, 2-carboxy-1,2,3,6-tetrahydropyridinyl, 2-carboxy-1,2,5,6-tetrahydropyridinyl, 2-carboxypiperidinyl, 2-carboxytetrahydroquinolinyl or 2-carboxyperhydroquinolinyl, 2-carboxy-2,3-dihydroindolyl or 2-carboxyperhydroindolyl as described herein, and in each of which the carboxy group may be functionalized in form of a pharmaceutically acceptable ester or amide; A represents a direct bond, lower alkenylene, lower alkylidene or lower alkylene provided that A does not represent a direct bond when Y represents 2-carboxypyrrolidinyl; and pharmaceutically acceptable salts thereof; which are useful for the treatment of nervous system disorders in mammals and as antagonists of the N-methyl-D-aspartate sensitive excitatory amino acid receptor.

4-(Phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxylic acids: Synthesis, activity at N-methyl-D-aspartic acid receptors, and anticonvulsant activity

A series of 4-(phosphonoalkyl)- and 4-(phosphonoalkenyl)-2-piperidinecarboxyl acids were synthesized, and their biological activity was assessed as competitive ligands for the NMDA receptor, both in vitro by using a receptor binding assay [(3H]CGS 19755 binding) and in vivo by using an NMDA seizure model in mice. The analogues were also evaluated in [3H]AMPA and [3H]kainate binding to assess their affinity for non-NMDA excitatory amino acid receptor subtypes. A number of these analogues show potent and selective NMDA antagonistic activity both in vitro and in vivo. Most notable are 4-(phosphonomethyl)-2-piperidinecarboxylic acid (1a) (CGS 19755) and the phosphonopropenyl analogue 1i, both of which show anticonvulsant activity in the 1-2 mg/kg ip range. With the aid of computer-assisted modeling, a putative bioactive conformation for AP-5 is hypothesized from the SAR data presented and a preliminary model for the antagonist-preferring state of the NMDA receptor is presented.